U.S. Stock News

Recent financial media coverage has pushed LexinFintech Holdings (LX) into the spotlight as a penny stock candidate, with attention centering on its fundamentals and its role within consumer finance during broader market volatility. See our latest analysis for LexinFintech Holdings. Despite the recent media spotlight, LexinFintech Holdings has faced pressure, with a 90 day share price return of a 40.12% decline and a 1 year total shareholder return of a 54.17% decline, suggesting momentum has...

Spire Global (SPIR) is back in focus after the company launched nine satellites on SpaceX's Twilight mission, including its HyMS weather sensor and eight satellites supporting Myriota's global IoT connectivity network. See our latest analysis for Spire Global. That satellite launch comes on the back of a sharp swing in sentiment, with a 72.51% 30 day share price return and a 55.06% year to date share price return, even though the 1 year total shareholder return is still a 32.65% decline. If...

Earlier this month, FuelCell Energy ended the employment of its Executive Vice President, General Counsel and Corporate Secretary Joshua Dolger without cause, and appointed Amanda J. Schreiber to those roles effective January 12, 2026. Schreiber’s extensive experience guiding complex power projects, governance, and risk management at ContourGlobal brings a power-sector-focused legal and compliance perspective to FuelCell Energy’s leadership team. Next, we’ll examine how Schreiber’s...

Latest Earnings Snapshot and How It Fits the Story Regions Financial (RF) has wrapped up FY 2025 with fourth quarter revenue of US$1,806 million and EPS of US$0.59, alongside trailing 12 month revenue of US$7.1 billion and EPS of US$2.31 that frame the full year picture. Over recent quarters the company has seen revenue move from US$1,660 million in Q1 2025 to US$1,811 million in Q3 2025, and EPS range between US$0.51 and US$0.62. This gives investors a clear line of sight on how the top line...

If you are wondering whether Ziff Davis is a bargain or a value trap at its current US$37.48 share price, you are not alone. The stock has returned 3.6% over the last 7 days and 4.8% over the last 30 days. Year to date it is at 10.3%, with a 31.8% decline over 1 year and a 56.1% decline over 3 years. These mixed returns sit against an ongoing stream of corporate updates and portfolio activity that continue to keep Ziff Davis on investors' watchlists. Together, these developments help explain...

Conference spotlight and why investors are watching LightPath Technologies (LPTH) is set to present at the 28th Annual Needham Growth Conference at The Lotte New York Palace Hotel in New York, and that upcoming appearance is drawing fresh attention from investors. See our latest analysis for LightPath Technologies. That conference appearance comes after a sharp run in the shares, with a 30 day share price return of 82.70% and a 1 year total shareholder return of 273.00%. This suggests...

Why EVERTEC (EVTC) is on investors’ radar today EVERTEC (EVTC) has drawn investor attention after its latest financial metrics highlighted solid transaction processing activity across Latin America and the Caribbean, with annual revenue of US$903.381m and net income of US$146.091m. Those headline figures, combined with mixed recent share returns and an assigned value score of 5, are prompting investors to reassess how this regional payments and fintech provider fits into a diversified...

If you are wondering whether AdaptHealth's share price lines up with its underlying worth, you are not alone. This article focuses squarely on what the current price might be implying about value. The stock last closed at US$10.61, with returns of 1.1% over 7 days, 1.2% over 30 days, 9.7% year to date and 0.9% over 1 year. These figures are set against much weaker 3 year and 5 year returns of 49.5% and 72.1% declines. Recent coverage has focused on AdaptHealth's position in the home...

If you are wondering whether W.W. Grainger at around US$1,068.72 is priced for strength or stretched, you are not alone. This article is built to help you frame that question clearly. The stock has returned 3.8% over the last 7 days, 4.8% over the last 30 days, 6.5% year to date, but shows a 3.2% decline over the last year, while longer periods such as 3 years and 5 years sit at 96.0% and 187.0% respectively. Recent coverage of W.W. Grainger has centered on its role as a key industrial...

Why Marqeta’s New CFO Matters for Investors Marqeta (MQ) has appointed Patti Kangwankij as Chief Financial Officer, effective February 9, 2026. This leadership change puts an experienced technology and payments executive at the center of its financial decision making. See our latest analysis for Marqeta. Despite the CFO appointment setting a fresh tone for execution, Marqeta’s recent 30 day share price return of 9.35% and year to date share price return of 3.88% are weaker, while the 1 year...

BlackRock (BLK) has wrapped up FY 2025 with fourth quarter revenue of US$7.0b and basic EPS of US$7.26, while trailing 12 month figures show revenue of US$24.2b and EPS of US$35.83. Over recent periods, revenue has moved from US$20.4b in the trailing 12 months to Q4 2024 to US$24.2b by Q4 2025, with basic EPS shifting from US$42.45 to US$35.83 over the same comparison window. With trailing net profit margin at 22.9%, down from 31.2% a year earlier, the latest results pair solid top line...

If you are wondering whether Somnigroup International at around US$94 is priced for perfection or still offers value, this breakdown will help you frame that question clearly. The share price comes with a 0.2% return over the last 7 days, 5.6% over 30 days, 5.9% year to date and 59.0% over the past year, with a 3 year return of 152.1% and 5 year return of 243.0% that many investors will want to put into context. Recent coverage has focused on Somnigroup International's position within its...

Why Compass Therapeutics Is On Investors’ Radar Compass Therapeutics (CMPX) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months despite reporting a net loss and no revenue. See our latest analysis for Compass Therapeutics. At a share price of $5.70, Compass Therapeutics has a 30 day share price return of 14.92% and a 90 day share price return of 33.80%. Its 1 year total shareholder return of 119.23% suggests...

Mereo BioPharma Group (NasdaqCM:MREO) has come into focus after releasing mixed Phase 3 results for setrusumab in osteogenesis imperfecta, along with a cash runway update to mid-2027 and progress on its alvelestat and vantictumab programs. See our latest analysis for Mereo BioPharma Group. The mixed Phase 3 readout and cash runway update come after a volatile stretch for the stock, with a 7 day share price return of 29.45% following a 30 day share price return decline of 66.67%, and a 1 year...

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...

Private Bancorp of America (PBAM) has wrapped up FY 2025 with fourth quarter revenue of US$29.9 million and basic EPS of US$1.75, alongside trailing twelve month revenue of US$119.2 million and EPS of US$7.09. Over recent periods, the company has seen quarterly revenue move from US$26.8 million in Q3 2024 to just over US$30.5 million in Q2 2025, with quarterly EPS ranging from about US$1.64 to US$1.83 over that span. This sets a clear earnings base for investors to work from. With a trailing...

If you are wondering whether InterDigital's share price still offers value at current levels, you are not alone. This article walks through what that price might imply about the stock. After a strong 81.7% return over the past year and a very large 3-year gain of about 4x, the stock has recently cooled, with a 0.1% 7-day slip, a 5.0% decline over 30 days, and a 5.4% fall year to date from a last close of US$308.76. Recent attention on InterDigital has been shaped by ongoing interest in...

J.B. Hunt Transport Services (JBHT) just wrapped up FY 2025 with fourth quarter revenue of US$3.1b and basic EPS of US$1.90, alongside net income of US$181.1m. The company has seen quarterly revenue move from US$3.1b in Q4 2024 to US$3.1b in Q4 2025, while basic EPS shifted from US$1.53 to US$1.90 over the same period. Trailing twelve month EPS stands at US$6.12 on revenue of US$12.0b. With net margin at 5.0% and slightly higher than last year, the focus this season is on how efficiently...

Mountain Pacific Bancorp (MPCB) just wrapped up FY 2025 with fourth quarter revenue of about US$10.0 million and net income of US$3.1 million, set against a trailing twelve month total of US$38.7 million in revenue and US$13.1 million in net income. The company has seen revenue move from US$28.7 million to US$38.7 million on a trailing basis, while trailing earnings growth of 67.1% and a net profit margin of 33.9% frame a results season in which profitability and efficiency are front and...

If you are wondering whether SouthState Bank's share price reflects its true worth, you are not alone. This article walks through what the current market price might be implying about value. The stock last closed at US$98.43, with returns of 0.8% over the past week, 0.8% over the last month, 4.5% year to date and 1.2% over the past year, while the 3 year and 5 year returns sit at 37.1% and 40.1% respectively. Recent moves in U.S. regional bank shares have kept investor attention on balance...

Recently, Chime Financial reported slowing growth and sequential declines in purchase volume, prompting investors to reassess the fintech’s competitive position and outlook. At the same time, Chime is pushing into higher-margin products, in-house payment processing, and AI-driven features to broaden its customer base and improve unit economics. We’ll now examine how Chime’s shift to its own payment processing platform could influence the company’s investment narrative and long-term...

In recent days, LeMaitre Vascular has been highlighted for its focus on innovation and international expansion in vascular surgery devices, while some observers point to its relatively small revenue base and elevated valuation multiples versus larger peers. An interesting angle is how renewed analyst confidence, centered on the company’s specialized product portfolio and global growth ambitions, contrasts with concerns about subscale operations and pricing power dependence. We’ll now examine...

In recent days, Wells Fargo upgraded its rating on Cintas to “Overweight,” signaling increased confidence in the company’s financial outlook and market position as a provider of corporate identity uniforms and related services. This shift in analyst stance highlights how Cintas’s outsourcing-focused business model and service breadth are influencing professional views on its longer-term prospects. Next, we’ll examine how Wells Fargo’s more positive view of Cintas’s market position may...

Why Ingevity stock is drawing attention now Ingevity (NGVT) has been catching investor attention after recent share price moves, with the stock closing at $66.17 and showing double digit total returns over the past year and past 3 months. See our latest analysis for Ingevity. Recent trading has been strong, with a 30 day share price return of 13.56% and a 90 day share price return of 21.82%. The 1 year total shareholder return of 40.19% contrasts with weaker 3 and 5 year total shareholder...